SHC · Sotera Health Co
$17.49
+0.20 (+1.16%)
At close · Jul 23
Market Cap
$4.99B
Shares
285.17M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$1.16B
+5.7%
FY2025
Net Income
$77.95M
+75.6%
FY2025
Gross Margin
55.48%
+0.8pp
FY2025
Operating Margin
27.05%
+0.7pp
FY2024
Diluted EPS
$0.27
+68.8%
FY2025
Operating Cash Flow
$287.2M
+28.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|---|
| $1.23B – $1.25B | $1.19B | $1.16B | $1.1B | $1.05B | $1B | $931.48M | $818.16M | $778.33M | |
| — | $531.97M | $518.08M | $498.15M | $472.13M | $446.68M | $412.81M | $374.59M | $382.9M | |
| — | $657.17M | $645.53M | $602.3M | $577.16M | $557M | $518.67M | $443.57M | $395.43M | |
| — | — | 55.48% | 54.73% | 55% | 55.5% | 55.68% | 54.22% | 50.81% | |
| — | $257.91M | $252.76M | $242.63M | $236.67M | $245.71M | $198.16M | $178.53M | $147.48M | |
| — | — | $41.8M | $79.38M | $81.35M | $81.55M | $86.74M | $80.25M | $80.05M | |
| — | — | $94.9M | $84.3M | $76.6M | $64.3M | $64.2M | $63.3M | $66.7M | |
| — | — | — | $304.67M | $300.47M | $308.65M | $261.94M | $237.55M | $211.83M | |
| — | — | — | $297.63M | $276.69M | $248.35M | $256.73M | $206.02M | $183.6M | |
| — | — | — | 27.05% | 26.37% | 24.74% | 27.56% | 25.18% | 23.59% | |
| — | — | — | $381.93M | $353.29M | $312.65M | $320.93M | $269.32M | $250.3M | |
| — | $9.27M | $8.55M | $5.31M | $7.37M | $6.44M | $15.2M | $9.41M | $7.25M | |
| — | $204.94M | $147.51M | $113.87M | $106.03M | -$243.11M | $175.72M | -$38.86M | -$916K | |
| — | $87.14M | $69.56M | $69.48M | $54.65M | -$9.54M | $58.6M | -$1.37M | $19.51M | |
| — | $117.8M | $77.95M | $44.4M | $51.38M | -$233.57M | $116.88M | -$38.62M | -$20.85M | |
| — | — | 6.7% | 4.03% | 4.9% | -23.27% | 12.55% | -4.72% | -2.68% | |
| — | — | — | — | $0 | $0 | $239K | $1.13M | $425K | |
| — | $117.79M | $77.95M | $44.34M | $51.09M | -$233.57M | $115.36M | -$38.62M | -$20.85M | |
| — | — | $176.36M | -$71.17M | $65.35M | -$256.66M | $127.16M | -$38.07M | -$5.28M | |
| USD/shares | — | — | $0.27 | $0.16 | $0.18 | -$0.83 | $0.41 | -$0.16 | -$0.09 |
| USD/shares | — | — | $0.27 | $0.16 | $0.18 | -$0.83 | $0.41 | -$0.16 | -$0.09 |
| shares | — | — | 283.96M | 282.78M | 281.01M | 280.1M | 279.23M | 237.7M | 232.4M |
| shares | — | — | 286.42M | 284.91M | 283.22M | 280.1M | 279.38M | 237.7M | 232.4M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2019–FY2022: $34M in buybacks, $691.17M in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
5.73×
Diagnostics & Research median 2.91×
EV/EBIT
—
Diagnostics & Research median 31.40×
P/E (TTM)
42.66×
Diagnostics & Research median 32.80×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Sterigenics | $755,780,000 | $697,853,000 | $667,130,000 | $626,646,000 | $571,829,000 | $498,773,000 | $471,708,000 |
| Nelson Labs | $220,219,000 | $229,233,000 | $221,699,000 | $223,402,000 | $219,142,000 | $204,640,000 | $190,454,000 |
| Nordion | $187,618,000 | $173,355,000 | $160,459,000 | $153,639,000 | $140,507,000 | $114,745,000 | $116,165,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| United States | $629,543,000 | $616,684,000 | $590,967,000 | $579,018,000 | $527,907,000 | $490,498,000 | $473,958,000 |
| Europe | $232,179,000 | $196,011,000 | $187,542,000 | $166,025,000 | $161,810,000 | $135,720,000 | $122,606,000 |
| Canada | $221,948,000 | $208,886,000 | $192,050,000 | $188,741,000 | $177,875,000 | $135,938,000 | $130,469,000 |
| Other Geographical Areas | $79,947,000 | $78,860,000 | $78,729,000 | $69,903,000 | $63,886,000 | $56,002,000 | $51,294,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Service | $995,756,000 | $941,822,000 | $905,598,000 | $864,828,000 | $805,501,000 | $713,520,000 | $673,037,000 |
| Product | $167,861,000 | $158,619,000 | $143,690,000 | $138,859,000 | $125,977,000 | $104,638,000 | $105,290,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Sterigenics | $412,893,000 | $378,171,000 | $362,212,000 | $339,144,000 |
| Nordion | $107,578,000 | $101,220,000 | $96,678,000 | $89,477,000 |
| Nelson Labs | $73,330,000 | $69,183,000 | $69,139,000 | $77,628,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Sterigenics | 54.6% | 54.2% | 54.3% | 54.1% |
| Nelson Labs | 33.3% | 30.2% | 31.2% | 34.7% |
| Nordion | 57.3% | 58.4% | 60.3% | 58.2% |
Key facts
CIK
1822479
CUSIP
83601L102
13F (30d)
48 filings
48 filers
Visit website
Investor relations